CERENO SCIENTIFIC AB B Total Assets
CERENO SCIENTIFIC AB B total assets. Based on the latest financial reports, CERENO SCIENTIFIC AB B (4A1) holds total assets worth €459.52 Million EUR (≈ $537.23 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CERENO SCIENTIFIC AB B market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of CERENO SCIENTIFIC AB B (2021–2025)
Total assets of CERENO SCIENTIFIC AB B from 2021 to 2025. This chart illustrates how CERENO SCIENTIFIC AB B's total assets have evolved over time, based on quarterly financial data. See CERENO SCIENTIFIC AB B share price for real-time trading data and today's change.
CERENO SCIENTIFIC AB B - Asset Composition Analysis
CERENO SCIENTIFIC AB B Total Assets Breakdown (December 2025)
CERENO SCIENTIFIC AB B total assets breakdown as of December 2025. CERENO SCIENTIFIC AB B's total assets of €459.52 Million consist of 19.5% current assets and 80.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 18.5% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €321.44 Million | 79.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how CERENO SCIENTIFIC AB B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 4A1 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CERENO SCIENTIFIC AB B's current assets represent 19.5% of total assets in 2025, a decrease from 50.5% in 2021.
- Cash Position: Cash and equivalents constituted 18.5% of total assets in 2025, down from 49.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 79.0% of total assets, an increase from 49.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 79.8% of total assets.
CERENO SCIENTIFIC AB B Competitors by Total Assets
Key competitors of CERENO SCIENTIFIC AB B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
CERENO SCIENTIFIC AB B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.51 | 5.98 | 3.25 |
| Quick Ratio | 0.51 | 5.98 | 3.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-41.89 Million | €65.73 Million | €54.33 Million |
CERENO SCIENTIFIC AB B - Advanced Valuation Insights
This section examines the relationship between CERENO SCIENTIFIC AB B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.59 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -2.7% |
| Total Assets | €402.67 Million |
| Market Capitalization | $60.94 Million USD |
Valuation Analysis
Below Book Valuation: The market values CERENO SCIENTIFIC AB B's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: CERENO SCIENTIFIC AB B's assets decreased by 2.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for CERENO SCIENTIFIC AB B (2021–2025)
The table below shows the annual total assets of CERENO SCIENTIFIC AB B from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €402.67 Million ≈ $470.77 Million |
-2.68% |
| 2024-12-31 | €413.77 Million ≈ $483.74 Million |
+45.19% |
| 2023-12-31 | €284.99 Million ≈ $333.18 Million |
+32.15% |
| 2022-12-31 | €215.65 Million ≈ $252.12 Million |
+19.32% |
| 2021-12-31 | €180.74 Million ≈ $211.30 Million |
-- |
About CERENO SCIENTIFIC AB B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company's lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as a… Read more